Healthcare Triangle, Inc. is holding a Special Meeting on October 23, 2026 to seek stockholder approval for a reverse stock split (1:2 to 1:25), authorization for up to $100M in dilutive financing issuances under Nasdaq Rule 5635(d), and an amendment to the 2020 Stock Incentive Plan to prevent reverse-split adjustments from reducing future award shares. The company is at risk of Nasdaq delisting due to non-compliance with the $1.00 minimum bid price rule, and these proposals are critical for maintaining its listing and accessing capital.
Price Chart
Executive Summary
Healthcare Triangle, Inc. is holding a Special Meeting on October 23, 2026 to seek stockholder approval for a reverse stock split (1:2 to 1:25), authorization for up to $100M in dilutive financing issuances under Nasdaq Rule 5635(d), and an amendment to the 2020 Stock Incentive Plan to prevent reverse-split adjustments from reducing future award shares. The company is at risk of Nasdaq delisting due to non-compliance with the $1.00 minimum bid price rule, and these proposals are critical for maintaining its listing and accessing capital.
Key Facts
- Special Meeting on October 23, 2026 to vote on reverse stock split (1:2 to 1:25), 20% Issuance Proposal, and 2020 Stock Incentive Plan amendment
- Reverse split intended to increase share price to maintain Nasdaq listing compliance (minimum $1.00 bid price)
- 20% Issuance Proposal authorizes up to 250M shares of common stock, 250M shares upon warrant exercise, and $100M in total issuance at up to 80% discount to market
- 2020 Stock Incentive Plan amendment would prevent reverse-split adjustments from reducing shares available for future awards
- As of October 5, 2026 record date: 17,730,008 common shares and 20,000 Series A Super Voting Preferred shares outstanding
- Suresh Venkatachari holds 100% of Series A Super Voting Preferred (20,000 shares) and 6 common shares, controlling 53.01% of total voting power
- Failure to approve reverse split would likely result in Nasdaq delisting
- Board reserves right to abandon reverse split even if approved
Financial Impact
Not specified
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001213900-26-109104 |
| Document: 0001213900-26-109104-index-headers.html | 0001213900-26-109104 |
| Document: 0001213900-26-109104-index.html | 0001213900-26-109104 |
| Document: 0001213900-26-109104.txt | 0001213900-26-109104 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | DEF 14A | $0.3820 | awaiting T+20 | — | $6.96 (−1721.99%) |
Oct 2, 2026 24d ago | 8-K | $0.6069 | awaiting T+20 | — | $6.96 (−1046.81%) |
Oct 1, 2026 26d ago | EFFECT | $0.7016 | awaiting T+20 | — | $6.96 (−892.02%) |
Aug 13, 2026 10w ago | Press Release | $1.73 $0.7457 | ▲ +56.90% | ▲ +55.15% | $6.96 (−302.31%) |
Jul 29, 2026 12w ago | 8-K | $1.56 $0.8683 | ▲ +44.34% | ▲ +49.36% | $6.96 (−346.15%) |
Jul 27, 2026 13w ago | Press Release | $1.70 $0.8446 | ▼ −50.32% | ▼ −53.62% | $6.96 (+309.41%) |
Jul 16, 2026 14w ago | EFFECT | $1.89 $1.73 | ▲ +8.47% | ▲ +12.08% | $6.96 (−268.25%) |
Jun 26, 2026 17w ago | 8-K | $1.88 $1.62 | ▲ +13.83% | ▲ +13.55% | $6.96 (−270.21%) |
Jun 15, 2026 19w ago | 8-K | $2.30 $1.74 | ▲ +24.35% | ▲ +24.55% | $6.96 (−202.61%) |
Apr 16, 2026 27w ago | 10-K/A | $2.47 $2.28 | ▲ +7.69% | ▲ +13.06% | $6.96 (−181.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers